Targeted therapies for inflammatory diseases

Improving lives with focused research

Inflammasomes are a root cause of inflammation

Inflammation leads to many of our most debilitating diseases

At Inflazome, we are dedicated to improving people’s lives by delivering new medicines that stop inflammation. Our founders are globally acknowledged scientific leaders whose vision is to transition their work from the lab to life.

Focused Research Today.
Better Results Tomorrow.

Our mission at Inflazome is to identify and develop potent, best-in-class, small molecule NLRP3 modulators as treatments for a broad range of inflammatory diseases.

Discover the Science

The Challange of Targeting Inflammation

When immune cells recognise an infection or harmful substances in the body that needs to be neutralised, inflammasomes – protein complexes in these immune cells – generate signals that cause inflammation and recruit other cells to help. This short term, beneficial inflammation allows the cells to fight and clear the infection or foreign particles, restoring us to good health.

However, unwanted inflammation can happen if immune cells are activated out of control. Inflammasomes generate signals calling for reinforcements whenever immune cells are stimulated. Sometimes the cells are over-stimulated, and in this case, the resulting overactive inflammatory response can damage healthy tissue, which in turn causes more inflammasomes to trigger, creating more inflammation.

Our mission is to stop this cycle of harmful inflammation and the development of associated diseases. The NLRP3 inflammasome has been identified as a key driver of this process, and has been implicated in a large number of diseases. At Inflazome we are identifying and developing potent, best-in-class, small molecule NLRP3 inhibitors to stop inflammation before it gets out of control.

The Impact of Inflammation

3 Million

The number of US adults reported being diagnosed with inflammatory bowel disease (either Crohn’s disease or ulcerative colitis) or 1.3% of the adult population.

8 Million

People living with Parkinson’s disease worldwide.

8%

In 2015-2016, approximately 8% of the US adult population reported some form of cardiovascular disease (including coronary heart disease, angina, previous myocardial infarction or stroke).

Our Pursuits

  1. Leadership Strength
    We have a dedicated and highly experienced management team committed to developing therapeutics with a high impact for patients.

  2. World-Class Research
    Our research has lead us to develop a pipeline of best-in-class inhibitors of the NLRP3 inflammasome to treat inflammatory diseases.

  3. Pioneering Development
    We are focused on developing proprietary, industry-leading, orally available drugs that block activation of the NLRP3 inflammasome in order to address unmet medical needs in inflammatory diseases.

The Pipeline

Inflazome is a true platform company underpinned by a robust pipeline of potent and proprietary small molecule NLRP3 inhibitors.

Inzomelid

Inzomelid is a potent, selective, brain-penetrant NLRP3 inhibitor that is currently in Phase I trials.

Somalix

Somalix is a potent, selective, peripherally restricted NLRP3 inhibitor that is currently in Phase I trials.

3rd Candidate

Our 3rd candidate is a potent, selective, peripherally restricted NLRP3 inhibitor.

Our Medicines

Since Inflazome was founded in 2016, we have invested heavily in our Medicinal Chemistry activities and Intellectual Property filings. We now have two clinical-stage therapeutic candidates - one brain penetrant and one peripherally restricted - that we expect to address unmet medical needs in multiple disease areas. Looking ahead, we plan to advance additional gut-restricted and topical molecules to cover additional diseases where NLRP3 activation is a key driver.

See the Pipeline

Inzomelid

A potent, selective, brain penetrant NLRP3 inhibitor with brain penetrating properties.

Somalix

A potent, selective, peripherally restricted NLRP3 inhibitor.

3rd Candidate

A potent, selective, peripherally restricted NLRP3 inhibitor.

Research

Inflazome is exploring tissue-specific inhibitors for Gastro-Intestinal (IBD, Crohn’s) and Dermatological (Psoriasis, Atopic Dermatitis) diseases.

We always strive to move scientific discoveries as quickly as possible from the lab to the clinic. We are committed to making a significant difference to patient’s lives.

Dr Matthew Cooper
Co-founder & Chief Executive Officer

Our Partnerships

Inflazome has partnered with the Michael J. Fox Foundation for Parkinson’s Research, who provided funding in excess of US$1 million to support the development of a brain imaging probe. This will be used to support clinical trials to treat neurodegenerative diseases.

We are open to partnering with Biotech and Pharma companies with excellent clinical development capabilities.

Our Partnerships

An imaging tool to visualise neuroinflammation may help investigate Parkinson’s onset and progression as well as evaluate new treatments that could alter the course of the disease. Our Foundation is investing in this research due to the significant potential impact on drug development and patient lives.

Dr Jamie Eberling
Director of Research Programs
Michael J. Fox Foundation for Parkinson’s Research

Follow our Progress & Insights

Inflazome is making rapid progress in advancing our clinical and preclinical assets. Keep up with the latest news on Inflazome’s research and development activities with regular email updates.

Speak to us about
a better tomorrow

Contact Us

×